Eledon Reports New Data on Tegoprubart for Islet Transplant in Type 1 Diabetes

Eledon Pharmaceuticals presented updated findings from an investigator-initiated trial testing tegoprubart in patients with Type 1 diabetes who received islet cell transplants. The data was shared at the 2026 American Diabetes Association Scientific Sessions.

cure researchbeta cellsadvancements

Key takeaways

Tegoprubart, an investigational drug, is being studied as a potential support for islet cell transplantation in Type 1 diabetes
Updated trial data from an independent research team was presented at a major diabetes conference in 2026
Islet transplantation is an approach being researched to help manage Type 1 diabetes, though it remains under investigation
This represents ongoing clinical research; tegoprubart has not been approved for this use

What Is Tegoprubart?

Tegoprubart is an investigational drug being developed by Eledon Pharmaceuticals. In this trial, it was tested alongside islet cell transplantation, a procedure in which insulin-producing cells from a donor pancreas are transplanted into a patient with Type 1 diabetes.

The Islet Transplant Trial

The trial presenting updated data was investigator-initiated, meaning it was designed and led by independent research teams rather than directly by Eledon. Results were shared at the American Diabetes Association's 2026 Scientific Sessions, a major annual conference where diabetes researchers present findings.

What This Means

Islet transplantation and supporting medications like tegoprubart represent one avenue of ongoing research for Type 1 diabetes management. While these approaches show promise in clinical studies, they remain investigational. People interested in learning more about islet transplantation or clinical trials should discuss options with their healthcare team.

Evidence label

Origin: Yahoo Finance (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.